<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421928</url>
  </required_header>
  <id_info>
    <org_study_id>CR013402</org_study_id>
    <secondary_id>R331333PAI3008</secondary_id>
    <secondary_id>KF11</secondary_id>
    <nct_id>NCT00421928</nct_id>
  </id_info>
  <brief_title>Tapentadol (CG5503)</brief_title>
  <official_title>A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gr√ºnenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety
      of orally administered tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250
      mg twice daily in patients with moderate to severe chronic pain due to osteoarthritis of the
      knee, in comparison with placebo and Oxycodone Controlled Release (CR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this randomized (study medication assigned to patients by chance),
      double-blind (neither patient nor investigator knows the study medication) , phase III,
      placebo and active controlled trial is to evaluate the efficacy and safety of orally
      administered tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice
      daily in patients with moderate to severe chronic pain from osteoarthritis (OA) of the knee.
      The study is being conducted for registration and approval of tapentadol (CG5503) in the US
      and outside the US. The trial will consist of five periods: screening (to assess eligibility)
      , washout (3-7 days with determination of a baseline pain intensity), titration (of dose over
      3 weeks to the optimal individual level) , maintenance (investigational drug intake for 12
      weeks with adjustments allowed), and follow-up (2 weeks post treatment discontinuation). The
      study hypothesis is that the study drug will be more effective than placebo in reducing
      patients pain intensity. The Secondary objectives include the collection of pharmacokinetic
      (related to how the body uses the drug) information for dose verification. The trial
      objectives will be assessed by comparing the baseline pain level to the level of week 12 of
      the maintenance phase. This will be done by looking at the patient's pain diary information.
      Titrate tapentadol (CG5503) ER (extended release) 50mg to patient's optimal dose ranging
      between 100mg and 250mg twice a day; Oxycodone CR (controlled release) 10mg to 50mg twice a
      day; Placebo (no active ingredients). All doses of trial treatment will be taken orally with
      approximately 120 mL of water with or without food for a maximum timeframe of 15 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12.</measure>
    <time_frame>Baseline and 12 weeks (Primary endpoint is the average pain intensity score during the last week of the maintenance period).</time_frame>
    <description>For this twice daily pain assessment, the subjects were to indicate the level of pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated &quot;no pain&quot; and a score of 10 indicated &quot;pain as bad as you can imagine&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Western Ontario McMaster Questionnaire (WOMAC) Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week of the Maintenance Period at Week 12</measure>
    <time_frame>Baseline and 12 week endpoint</time_frame>
    <description>Change from baseline to Week 12 of WOMAC Global Score: WOMAC is measure with a Likert ordinal scale from 0-4 with lower scores indicating lower levels of symptoms or physical disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sleep Latency Time in Hours Over the Last Week of the Maintenance Period at Week 12.</measure>
    <time_frame>Baseline and 12 week endpoint</time_frame>
    <description>A Sleep Questionniare addressed the following question: &quot;How long after bedtime/lights out did you fall asleep last night (hours)?&quot; 12 week endpoint-mean changes from baseline at endpoint for sleep latency. Decrease in time(hours) indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Reported Very Much Improved or Much Improved From Baseline in Patient Global Impression of Change Over the Last Week of the Maintenance Period at Week 12</measure>
    <time_frame>Baseline and 12 week endpoint</time_frame>
    <description>Ordinal measure indicating change from start of treatment (on a scale of 7 = Very much worse to 1 = Very much improved)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Time to Treatment Discontinuation Due to Lack of Efficacy</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>The median time to treatment discontinuation due to lack of efficacy from baseline to endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EuroQol-5 (EQ-5D) Health Status Index to Week 12</measure>
    <time_frame>Baseline and 12 week endpoint</time_frame>
    <description>Change from baseline to end point in EuroQol-5 (EQ-5D) Dimension Questionnaire. A higher score indicates an improvement in health in the Health Status Index. The EQ-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating &quot;full health&quot; and 0 representing dead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Responder Analysis 50% Improvement to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Defined by the percentage of subjects achieving at least 50% improvement from baseline in the primary endpoint based on the 11-point NRS at week 12. For this twice daily pain assessment, the subjects were to indicate the level of pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated &quot;no pain&quot; and a score of 10 indicated &quot;pain as bad as you can imagine&quot;.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1030</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tapentadol (CG5503) 50 100 150 200 250mg twice a day (BID) during 15 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oxycodone 10 20 30 40 50mg twice a day (BID) during 15 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo matching placebo twice a day (BID) during 15 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxycodone</intervention_name>
    <description>10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo twice a day (BID) during 15 weeks</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tapentadol (CG5503)</intervention_name>
    <description>50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with osteoarthritis of the knee based on the American College of
             Rheumatology (ACR) criteria and functional capacity class of I-III

          -  patients taking analgesic medications for at least 3 months prior to screening and/or
             dissatisfied with their current therapy

          -  Patients requiring opioid treatment must be taking daily doses of opioid-based
             analgesic, equivalent to &lt;160 mg of oral morphine

          -  baseline score of greater than or equal to 5 on an 11-point numerical rating scale,
             calculated as the average pain intensity during the last 3 days prior to
             randomization.

        Exclusion Criteria:

          -  History of alcohol and/or drug abuse in Investigator's judgement

          -  history of significant liver insufficiency

          -  chronic hepatitis B or C, or HIV, presence of active hepatitis B or C within the past
             3 months

          -  life-long history of seizure disorder or epilepsy

          -  history of malignancy within past 2 years, with exception of basal cell carcinoma that
             has been successfully treated

          -  uncontrolled hypertension

          -  patients with severely impaired renal function

          -  patients with moderate to severly impaired hepatic function or with laboratory values
             reflecting inadequate hepatic function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=69&amp;filename=CR013402_CSR.pdf</url>
    <description>A Randomized Double-Blind, Placebo &amp; Active-Control, Parallel-Arm Phase 3 Study With Controlled Dose Adjustment to Evaluate the Efficacy and Safety of Tapentadol Extended-Release (ER) in Subjects With Moderate to Severe Chronic Pain Due to OA of the Knee</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2007</study_first_submitted>
  <study_first_submitted_qc>January 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2007</study_first_posted>
  <results_first_submitted>July 8, 2009</results_first_submitted>
  <results_first_submitted_qc>April 5, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 23, 2010</results_first_posted>
  <last_update_submitted>April 16, 2012</last_update_submitted>
  <last_update_submitted_qc>April 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2012</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Leader</name_title>
    <organization>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</organization>
  </responsible_party>
  <keyword>Chronic Pain</keyword>
  <keyword>Osteoarthritis, Knee</keyword>
  <keyword>tapentadol</keyword>
  <keyword>Pain Assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period for this out-patient, multicenter study occurred between 07 February 2007 and 15 July 08.</recruitment_details>
      <pre_assignment_details>The study consisted of a screening period (duration up to 14 days), a washout period (duration 3 to 7 days), a double-blind active treatment period with titration period (duration 3 weeks) and maintenance period (duration 12 weeks)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tapentadol (CG5503)</title>
          <description>Tapentadol(CG5503) extended release (ER) 100-250mg twice daily (BID)</description>
        </group>
        <group group_id="P2">
          <title>Oxycodone</title>
          <description>oxycodone controlled release (CR)20-50mg twice daily (BID)</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matching Placebo twice daily (BID)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="344">2 randomly assigned to this treatment group did not receive drug</participants>
                <participants group_id="P2" count="342">2 randomly assigned to this treatment group did not receive drug. One subject was enrolled twice.</participants>
                <participants group_id="P3" count="337">2 randomly assigned to this treatment group did not receive drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="118"/>
                <participants group_id="P3" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="224"/>
                <participants group_id="P3" count="134"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="140"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study drug non-compliant</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>All other</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tapentadol (CG5503)</title>
          <description>Tapentadol(CG5503) extended release (ER) 100-250mg twice daily (BID)</description>
        </group>
        <group group_id="B2">
          <title>Oxycodone</title>
          <description>oxycodone controlled release (CR)20-50mg twice daily (BID)</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matching Placebo twice daily (BID)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="344"/>
            <count group_id="B2" value="342"/>
            <count group_id="B3" value="337"/>
            <count group_id="B4" value="1023"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="260"/>
                    <measurement group_id="B4" value="758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.4" spread="10.09"/>
                    <measurement group_id="B2" value="58.2" spread="10.29"/>
                    <measurement group_id="B3" value="58.2" spread="9.15"/>
                    <measurement group_id="B4" value="58.3" spread="9.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="200"/>
                    <measurement group_id="B4" value="618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12.</title>
        <description>For this twice daily pain assessment, the subjects were to indicate the level of pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated &quot;no pain&quot; and a score of 10 indicated &quot;pain as bad as you can imagine&quot;.</description>
        <time_frame>Baseline and 12 weeks (Primary endpoint is the average pain intensity score during the last week of the maintenance period).</time_frame>
        <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) was used to impute pain score after discontinuation</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol (CG5503)</title>
            <description>Tapentadol(CG5503) extended release (ER) 100-250mg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>oxycodone controlled release (CR)20-50mg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12.</title>
          <description>For this twice daily pain assessment, the subjects were to indicate the level of pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated &quot;no pain&quot; and a score of 10 indicated &quot;pain as bad as you can imagine&quot;.</description>
          <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) was used to impute pain score after discontinuation</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
                <count group_id="O2" value="342"/>
                <count group_id="O3" value="337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="2.39"/>
                    <measurement group_id="O2" value="-2.6" spread="2.38"/>
                    <measurement group_id="O3" value="-2.2" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary null hypothesis to be tested for the study was that the tapentadol ER group was not different from the placebo group for the primary endpoint. Assuming the mean treatment group difference of 0.7 with an SD of 2.7, 314 subjects per treatment group were estimated to provide 90% power to show that the tapentadol ER group was statistically different from placebo at an alpha level of 0.05. The total number of subjects to be randomly assigned to a treatment group for the study was 942.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) model was used with treatment and pooled analysis center as factors and baseline pain intensity score as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Western Ontario McMaster Questionnaire (WOMAC) Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week of the Maintenance Period at Week 12</title>
        <description>Change from baseline to Week 12 of WOMAC Global Score: WOMAC is measure with a Likert ordinal scale from 0-4 with lower scores indicating lower levels of symptoms or physical disability</description>
        <time_frame>Baseline and 12 week endpoint</time_frame>
        <population>Intent To Treat (ITT), observed cases analysis conducted, no imputation performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol (CG5503)</title>
            <description>Tapentadol(CG5503) extended release (ER) 100-250mg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>oxycodone controlled release (CR)20-50mg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario McMaster Questionnaire (WOMAC) Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week of the Maintenance Period at Week 12</title>
          <description>Change from baseline to Week 12 of WOMAC Global Score: WOMAC is measure with a Likert ordinal scale from 0-4 with lower scores indicating lower levels of symptoms or physical disability</description>
          <population>Intent To Treat (ITT), observed cases analysis conducted, no imputation performed.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.82"/>
                    <measurement group_id="O2" value="-1.1" spread="0.87"/>
                    <measurement group_id="O3" value="-0.9" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sleep Latency Time in Hours Over the Last Week of the Maintenance Period at Week 12.</title>
        <description>A Sleep Questionniare addressed the following question: &quot;How long after bedtime/lights out did you fall asleep last night (hours)?&quot; 12 week endpoint-mean changes from baseline at endpoint for sleep latency. Decrease in time(hours) indicates improvement.</description>
        <time_frame>Baseline and 12 week endpoint</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol (CG5503)</title>
            <description>Tapentadol(CG5503) extended release (ER) 100-250mg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>oxycodone controlled release (CR)20-50mg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sleep Latency Time in Hours Over the Last Week of the Maintenance Period at Week 12.</title>
          <description>A Sleep Questionniare addressed the following question: &quot;How long after bedtime/lights out did you fall asleep last night (hours)?&quot; 12 week endpoint-mean changes from baseline at endpoint for sleep latency. Decrease in time(hours) indicates improvement.</description>
          <population>ITT</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="337"/>
                <count group_id="O3" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.8"/>
                    <measurement group_id="O2" value="0.1" spread="1.81"/>
                    <measurement group_id="O3" value="0.3" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Reported Very Much Improved or Much Improved From Baseline in Patient Global Impression of Change Over the Last Week of the Maintenance Period at Week 12</title>
        <description>Ordinal measure indicating change from start of treatment (on a scale of 7 = Very much worse to 1 = Very much improved)</description>
        <time_frame>Baseline and 12 week endpoint</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol (CG5503)</title>
            <description>Tapentadol(CG5503) extended release (ER) 100-250mg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>oxycodone controlled release (CR)20-50mg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Reported Very Much Improved or Much Improved From Baseline in Patient Global Impression of Change Over the Last Week of the Maintenance Period at Week 12</title>
          <description>Ordinal measure indicating change from start of treatment (on a scale of 7 = Very much worse to 1 = Very much improved)</description>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1"/>
                    <measurement group_id="O2" value="37.7"/>
                    <measurement group_id="O3" value="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Time to Treatment Discontinuation Due to Lack of Efficacy</title>
        <description>The median time to treatment discontinuation due to lack of efficacy from baseline to endpoint</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <population>ITT: The results for median and interquartile ranges were not estimable because insufficient number of subjects discontinued due to lack of efficacy to estimate the values.</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol (CG5503)</title>
            <description>Tapentadol(CG5503) extended release (ER) 100-250mg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>oxycodone controlled release (CR)20-50mg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Time to Treatment Discontinuation Due to Lack of Efficacy</title>
          <description>The median time to treatment discontinuation due to lack of efficacy from baseline to endpoint</description>
          <population>ITT: The results for median and interquartile ranges were not estimable because insufficient number of subjects discontinued due to lack of efficacy to estimate the values.</population>
          <units>median time</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EuroQol-5 (EQ-5D) Health Status Index to Week 12</title>
        <description>Change from baseline to end point in EuroQol-5 (EQ-5D) Dimension Questionnaire. A higher score indicates an improvement in health in the Health Status Index. The EQ-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating &quot;full health&quot; and 0 representing dead</description>
        <time_frame>Baseline and 12 week endpoint</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol (CG5503)</title>
            <description>Tapentadol(CG5503) extended release (ER) 100-250mg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>oxycodone controlled release (CR)20-50mg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EuroQol-5 (EQ-5D) Health Status Index to Week 12</title>
          <description>Change from baseline to end point in EuroQol-5 (EQ-5D) Dimension Questionnaire. A higher score indicates an improvement in health in the Health Status Index. The EQ-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating &quot;full health&quot; and 0 representing dead</description>
          <population>ITT</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
                <count group_id="O2" value="342"/>
                <count group_id="O3" value="337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.26"/>
                    <measurement group_id="O2" value="0.5" spread="0.28"/>
                    <measurement group_id="O3" value="0.5" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Responder Analysis 50% Improvement to Week 12</title>
        <description>Defined by the percentage of subjects achieving at least 50% improvement from baseline in the primary endpoint based on the 11-point NRS at week 12. For this twice daily pain assessment, the subjects were to indicate the level of pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated &quot;no pain&quot; and a score of 10 indicated &quot;pain as bad as you can imagine&quot;.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>ITT. Subjects who discontinued from the study were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol (CG5503)</title>
            <description>Tapentadol(CG5503) extended release (ER) 100-250mg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>oxycodone controlled release (CR)20-50mg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Responder Analysis 50% Improvement to Week 12</title>
          <description>Defined by the percentage of subjects achieving at least 50% improvement from baseline in the primary endpoint based on the 11-point NRS at week 12. For this twice daily pain assessment, the subjects were to indicate the level of pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated &quot;no pain&quot; and a score of 10 indicated &quot;pain as bad as you can imagine&quot;.</description>
          <population>ITT. Subjects who discontinued from the study were considered non-responders.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
                <count group_id="O2" value="342"/>
                <count group_id="O3" value="337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0"/>
                    <measurement group_id="O2" value="17.3"/>
                    <measurement group_id="O3" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events were reported from the time a signed and dated informed consent was obtained throughout the follow-up phase of the study. Serious adverse events were collected for 30 days after the last dose of study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tapentadol (CG5503)</title>
          <description>Tapentadol(CG5503) extended release (ER) 100-250mg twice daily (BID)</description>
        </group>
        <group group_id="E2">
          <title>Oxycodone</title>
          <description>oxycodone controlled release (CR)20-50mg twice daily (BID)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Matching Placebo twice daily (BID)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Intestinal Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Withdrawal Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Embolic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Spinal Fusion Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="269" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="134" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="344"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="342"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, Clinical Leader</name_or_title>
      <organization>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</organization>
      <phone>609-730-4537</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

